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ABSTRACT 
 
Aim: Remote magnetic navigation (RMN) is a safe and effective means of performing 
ventricular tachycardia (VT) ablation. It may have advantages over manual methods 
due to ease of manoeuvrability and catheter stability. We sought to compare the safety 
and efficacy of RMN versus manual VT ablation. 
Methods: Retrospective study of procedural outcomes of 139 consecutive VT ablation 
procedures (69 RMN, 70 manual ablation) in 113 patients between 2009 and 2015 
was performed.  
Results: RMN was associated with overall higher acute procedural success (80% vs. 
60%, p=0.01), with a trend to fewer major complications (3% vs. 9% P=0.09). 79 
patients were followed up for a median of 17.0 (IQR 3.0 – 41.0) months for the RMN 
group and 15.5 (IQR 6.5-30.0) months for manual ablation group. In the ischaemic 
cardiomyopathy subgroup, RMN was associated with longer survival from the 
composite endpoint of VT recurrence leading to defibrillator shock, re-hospitalisation 
or repeat catheter ablation and all-cause mortality; single procedure adjusted HR 
0.240 (95% CI 0.070-0.821) p = 0.023, multi-procedure HR 0.170 (95% CI 0.046-
0.632) p = 0.002. In patients with implanted defibrillators, multi-procedure VT free 
survival was superior with RMN, HR 0.199 (95% CI 0.060-0.657) p = 0.003. 
Conclusion: Remote magnetic navigation may improve clinical outcomes after 
catheter ablation of VT in patients with ischaemic cardiomyopathy. Further 
prospective clinical studies are required to confirm these findings.  
 
 
  
CONDENSED ABSTRACT 
We performed a single centre retrospective study of safety and efficacy of remote 
magnetic navigation guided and manual VT ablation. Remote magnetic navigation 
was associated with higher procedural efficacy for ablation of VT in ischaemic 
cardiomyopathy. 
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WHAT’S NEW? 
• Remote magnetic navigation guided ablation can be safe and effective for the 
treatment of ventricular tachycardia. 
• Compared with manual ablation, remote magnetic navigation may enable 
more effective ablation of ventricular tachycardia in patients with ischaemic 
cardiomyopathy.  
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Ventricular tachycardia (VT) is a debilitating and life-threatening arrhythmia that is 
often poorly controlled by antiarrhythmic medications. Implanted cardiac 
defibrillators (ICD) reduces mortality by providing a means to terminate VT, however 
recurrent VT and ICD shocks reduced quality of life and are associated with increased 
mortality in patients with cardiomyopathy [1, 2]. Catheter ablation can be curative in 
idiopathic VT and reduce VT burden and appropriate ICD shocks in patients with 
ischaemic cardiomyopathy[3]. Current practice guidelines and expert consensus 
advocate the use of catheter ablation for symptomatic idiopathic VT and in the setting 
of incessant VT, electrical storm or recurrent ICD shocks in patients with VT and 
structural heart disease[4, 5].  
 
The use of a remote magnetic navigation system may have benefits over manual 
catheter ablation. Comparative studies performed in retrospective cohorts, case 
control studies and small randomised control trials report in general lower rates of 
major complications and radiation dose using remote magnetic navigation for catheter 
ablation of a range of cardiac arrhythmias[6-9]. For VT ablation procedures, there is 
emerging evidence that remote magnetic navigation may also be associated with 
reduced procedure duration and higher or comparable acute and long term success[10, 
11]. In vitro data suggest that remote magnetic navigation provides more stable 
catheter position in the ventricle which would be advantageous for mapping and 
lesion formation[12]. We therefore compared acute procedural and long-term 
outcomes after manual and remote magnetic navigation guided VT ablations at our 
centre, which performs both manual and remote magnetic navigation ablation. 
METHOD 
Patient cohort  
This retrospective study was approved by the Western Sydney Local Health District 
Human Ethics Committee. Consecutive VT ablations procedures at Westmead 
Hospital between 1st January 2009 and 24th September 2015 were included. All 
patients provided informed consent for the procedure.  
 
Catheter ablation procedure 
VT ablation procedures were performed under general anaesthesia. Intravenous 
heparin was administered to maintain activated clotting time 300-350s if the left 
ventricle was accessed endocardially. CARTO system (Biosense Webster Inc., 
Diamond Bar, CA, USA) and EnSite NAVX 3D (St Jude Medical, St. Paul, MN, 
USA) were used for electroanatomical mapping. Areas of ventricular scar was 
identified by endocardial bipolar voltages <1.5mV (dense scar <0.5mV) and unipolar 
voltages <8.3mV (or <5.5mV for RV), and bipolar epicardial voltage <1mV[13, 14]. 
VT induction was performed with programed ventricular stimulation with a drive 
train cycle length of 400ms and up to 4 extrastimuli, each introduced at 300ms and 
decremented in 10ms steps down to ventricular refractoriness as previously 
described[15]. Isoprenaline with or without adrenaline infusion was required in some 
patients to induce focal VT. A combination of activation, entrainment, and pace 
mapping and was used to identify sites for catheter ablation. Substrate modification 
was also performed by targeting fractionated late potentials. The procedural endpoint 
was non-inducibility of the clinical VT. Other VTs were that were easily inducible 
and considered of potential clinical importance by the operator were also targeted for 
ablation.  
Patients were allocated to remote magnetic navigation or manual ablation based on 
lab availability and operator preference. Remote magnetic navigation guided ablation 
was performed using the 3.5mm Navistar thermocool RMT catheter (Biosense 
Webster Inc., Diamond Bar, CA, USA) with the Niobe SE (Stereotaxis, St Louis, 
MO, USA) from 1st January 2009 to 24th October 2013 and Niobe Epoch thereafter. 
Manual ablations were routinely delivered with 3.5 or 4mm tip irrigated 
radiofrequency ablation catheters. Typical ablation settings for manual ablations were 
30-50W in the right ventricle and 40-50W in the left ventricle for 30-60s, temperature 
limited to 40°C, irrigation 15-20mL/min. For remote magnetic navigation ablations, 
our practice is to use 40W for right ventricle and 50W for left ventricle and up titrate 
catheter irrigation flow rate from 15mL/min up to 30mL/min to maintain catheter tip 
temperature <40°C to maximise power delivery, as power delivery rather than 
catheter tip temperature governs lesion size during irrigated ablation[16]. Indications 
for ICD implantation was consistent with published society guidelines[17]. Detection 
algorithms and therapy settings varied with device model and manufacturer. In 
general to minimise device shock, therapy for nonsustained VT was avoided and 
antitachycardia pacing was used preferentially to terminate VT.  
 
Acute procedural and follow up data collection 
Demographic patient information and indications for the VT ablation procedure was 
extracted from admission records. The severity of left and right ventricular systolic 
impairment was determined from the transthoracic echocardiogram (TTE), 
(99mTc) sestamibi or gated heart pool scan performed in the 6 months prior to the 
procedure and graded as normal (≥55%), mild (45-54%), moderate (35-44%) or 
severe (<35%). The indication for VT ablations procedures was considered elective if  
planned as an outpatient, and an emergency if performed during unplanned admission 
to hospital for ventricular tachycardia. The VT ablation procedure report was used to 
determine the number of VT morphologies induced during the study, the access used 
for the ablation catheter, procedure duration (from the time of venous puncture to 
removal of catheters), fluoroscopy time, and acute procedural success. Procedural 
complications were determined from the discharge summary and procedure report. 
Complications were considered major if it resulted in death, required an urgent 
surgical procedure or lead to permanent neurological disability. Other complications 
such as access site bleeding managed conservatively, pericardial effusions that 
required pericardiocentesis but not surgical drainage and repair, or transient ischaemic 
attack were considered minor complications.  A combination of outpatient cardiology 
clinic data, device interrogation reports, hospital admissions coding data and 
discharge summaries for subsequent hospital admissions were used to determine the 
outcomes at follow up. 
Study endpoints 
The primary composite endpoint investigated was the single procedure and multi-
procedure freedom from VT recurrence leading to implanted defibrillator shock, re-
hospitalisation, or repeat VT ablation and all-cause mortality. This endpoint was 
chosen to encapsulate major clinical adverse outcomes associated with recurrent VT 
that reduce quality and length of life. For the single procedure analysis, the first 
ablation procedure was taken as the index procedure. In the multi-procedure analysis, 
the last ablation procedure where the patient received post-procedure follow up was 
taken as the index procedure. Patients were excluded from the multi-procedure 
analysis if both manual and remote magnetic navigation guided VT ablation 
procedures had been performed. The secondary endpoints were 1) acute procedural 
success; 2) procedural complications; 3) freedom from sustained VT in patients with 
ICDs defined as VT lasting longer than 30s or otherwise treated with device therapy 
(any antitachycardia pacing or defibrillator shock); and 4) freedom from all-cause 
mortality. The census date for follow data collection was November 17th 2016. 
Statistical analysis 
Analysis was performed with IBM SPSS Statistics Version 22 (IBM Corp, NY, USA).  
Categorical variables were compared between groups using Pearson’s chi square, or 
Fisher’s exact test if cell size was less than 5. Continuous variables were compared 
using Mann Whitney Test, or permutation t test using 10,000 samples if cell size was 
less than 5. Logistic regression analysis was used to determine multivariate predictors 
for acute procedural success and complications using univariate predictors with p<0.2. 
Kaplan-Meier survival analysis was performed and significant differences between 
groups determined using log rank test (Mantel-Cox). Cox regression analysis was 
performed to identify multivariate predictors using univariate predictors with p<0.2 
on log rank test. Statistical significance was taken as p<0.05.   
 
RESULTS 
Patient cohort 
Catheter ablation procedures for VT (N = 139) were performed in 113 patients. The 
etiology of VT was idiopathic in 38 patients, and included RV and LV outflow tract, 
fascicular, bundle branch re-entry, and papillary VTs; ischaemic cardiomyopathy in 
37 patients, and non-ischaemic cardiomyopathy in 38 patients. Manual ablation was 
used to perform 70 procedures and remote magnetic navigation for 69 procedures. 
The procedure was converted from remote magnetic navigation to manual in 2 cases 
due to perceived difficulty with achieving stable contact or adequate contact force. 
These were included as a part of the remote magnetic navigation group based on an 
intention to treat analysis. Baseline patient characteristics were similar between 
remote magnetic navigation guided and manual ablation groups. There were 
numerically more females and less non-ischaemic cardiomyopathy in the remote 
magnetic navigation group that did not reach significance. Both manual and remote 
magnetic navigation groups had a similar rate of  and elective VT ablation and redo 
procedures (Table 1 and 2). 
 
VT ablation procedure 
The remote magnetic navigation group had more cases with ³3 inducible VT 
morphologies, 16/69 (24%) vs. 5/70 (7%) p = 0.009; and had generally longer 
procedural duration and ablation times (Table 2). The use of more than one access 
approach for the ablation catheter was lower with remote magnetic navigation 
compared to manual ablation, 5/69 (7%) vs. 14/70 (20%) p = 0.029, with fewer cases 
that required retrograde aortic access, 7/69 (10%) vs. 18/70 (26%) p = 0.017. The 
manual ablation group had two cases that required bipolar ablation at the 
interventricular septum and in one case that used a transapical approach via mini-
thoracotomy. The mean procedure duration was longer with remote magnetic 
navigation, 429±121min vs. 291±101min p<0.001, but total fluoroscopy time was 
lower 32.45±24.24 vs. 38.8±24.08, p = 0.059, and lower per hour of procedure, 4.2±3 
min/hr vs. 7.8±3.6 min/hr p<0.001.  
 
Acute procedural outcomes 
Acute procedural success, defined as clinical VT non-inducibility, was higher in with 
remote magnetic navigation than manual ablation, 55/69 (80%) vs. 42/70 (60%) p = 
0.011, odds ratio 2.619 (1.229-5.583), and was the only significant factor in 
multivariate analysis. Remote magnetic navigation was also associated with a lower 
rate of unsuccessful ablation, 1/69 (1%) vs. 8/70 (11%), p = 0.033 (Tables 2 and 3).  
 
The procedural complication rate was similar between manual and remote magnetic 
navigation, 8/70 (11%) vs. 9/69 (13%) p = 0.801. There were numerically more major 
complications with manual ablation which did not reach significance, 6/70 (9%) vs 
2/69 (3%), p = 0.091 (Table 2). The risk of complications was higher for patients in 
the third age tertile (>67yrs), HR 4.524 (95%CI 1.220-24.359), undergoing redo VT 
ablations, HR 5.451 (95%CI 1.030-17.859), and have right ventricular impairment, 
HR 4.289 (95%CI 1.016-20.144) (Table 3). There were 2 deaths, both in the manual 
group; one due to cardiac perforation and tamponade during mapping of LV scar, and 
another from cardiogenic shock in a patient with severely impaired left ventricular 
function. Nonfatal pericardial tamponade occurred in 5 cases (4%), 3 with manual and 
2 with remote magnetic navigation. Pericardial bleeding occurred during catheter 
manipulation in the manual cases, whereas in the remote magnetic navigation cases, 
one occurred due to coronary laceration at epicardial access and the other after 
defibrillation thought to be secondary to a quadrapolar catheter perforating the right 
ventricle. Other complications in the cohort included 5 vascular access site 
complications (4%), two of which required surgical repair; 3 decompensations of 
cardiac failure requiring inotropic support post-procedurally; 1 case of high grade AV 
block after basal right ventricular septum ablation; 1 ventricular septal defect from 
bipolar ablation and aortic regurgitation caused by retrograde aortic access in a child; 
and 1 deep vein thrombosis. 
 
Outcomes at follow up 
Clinical follow-up data was available for 79 of 113 patients (36 manual and 43 remote 
magnetic navigation). The median follow-up duration in the manual group was 15.5 
(interquartile range 6.5 – 30.0) months and in the remote magnetic navigation group 
was 17.0 (interquartile range 3.0 – 41.0) months.  
 
In a single procedure analysis, there was a trend towards longer median survival from 
the primary composite endpoint in the remote magnetic navigation compared with 
manual ablation, 38.0 (95% CI 5.2-70.8) months vs. 15.0 (95% CI 8.6-21.3) months, 
p=0.412. Among patients with ischaemic cardiomyopathy, remote magnetic 
navigation was associated with longer median survival 27 (95% CI 7.2-46.8) months 
vs. 8 (95% CI 1.5-14.5) p = 0.104, which became significant after adjustment for 
covariates in multivariate analysis, adjusted HR 0.240 (95% CI 0.070-0.821) p = 
0.023 (Fig. 1, Table 3). Emergency indication for VT ablation was the only other 
multivariate predictor for the primary composite endpoint, HR 3.782 (95% CI 1.080-
13.252) p=0.038.  
 
In a multi-procedure analysis that excluded 8 cross-over patients, remote magnetic 
navigation showed significantly longer median survival from the primary composite 
endpoint, 46 (95% CI 41.6-50.4) months vs. 15.0 (95% CI 8.6-21.3) months, p = 
0.018. The benefit was driven by the effect of remote magnetic navigation in the 
ischaemic subgroup where the median survival was 43.0 (95% CI 17.1-68.9) months 
vs. 4.0 (95% CI 0-12.6) months, hazard ratio 0.170 (95% CI 0.046-0.632) (Fig. 2). No 
other significant multivariate predictors were identified. Among the 64 patients with 
ICDs, 34 had complete device follow up history at our center. Remote magnetic 
navigation was associated with longer multi-procedure freedom from sustained VT in 
patients with ischaemic cardiomyopathy, hazard ratio 0.199 (95% CI 0.060-0.657), p 
= 0.003 (Fig. 3). There were no significant differences in mortality between manual 
and remote magnetic navigation groups (Fig. 4). 
 
Operator bias 
At our centre, 7 proceduralists performed VT ablations. All were experienced with 
manual ablations and 5 had performed at least one remote magnetic navigation guided 
ablation. Two operators predominantly used remote magnetic navigation and 
performed 60/69 (87%) cases in the remote magnetic navigation group, one of whom 
performed 54/69 (78%) cases. Combined, they also performed 12/70 (17%) manual 
ablations. To assess whether the use of remote magnetic navigation was a stronger 
influence than operator preference on procedural outcomes, we repeated logistic 
regression analysis for acute procedural success and Cox regression analysis for 
single and multi-procedure hazard of reaching the primary composite endpoint 
comparing proceduralists who had performed more remote magnetic navigation 
guided ablations to those who performed more manual ablations. This did not 
significantly alter the results of the multivariate analyses. 
 
DISCUSSION 
This study is the first to find that remote magnetic navigation guided VT ablation was 
associated not only with higher overall acute procedural success but also better long-
term clinical outcomes and lower arrhythmia recurrence in the subgroup of patients 
with ischaemic cardiomyopathy. Remote magnetic navigation lead to higher rate of 
acute success compared with manual ablation, 80% vs 60% p = 0.011, and fewer 
unsuccessful ablations, 1/69 (1%) vs. 8/70 (11%) p = 0.033, defined as no change in 
clinical VT inducibility. At follow up, remote magnetic navigation guidance was 
associated with significantly longer survival from primary composite endpoint in the 
ischaemic cardiomyopathy subgroup for both single and multi-procedure analyses 
(Fig 1 and 2, Table 4). This was accompanied by longer freedom from sustained VT 
among patients with ICDs and ischaemic cardiomyopathy in a multi-procedure 
analysis (Fig 3).  
 
Earlier studies comparing remote magnetic navigation and manual VT ablation have 
consisted of mostly case series with a majority of idiopathic VT[6]. A meta-analysis 
of these studies showed a high and similar acute and long-term success with both 
remote magnetic navigation and manual ablation and a lower procedural complication 
rate, fluoroscopy use and procedural duration for remote magnetic navigation[18]. 
Majority of our patients had structural heart disease where acute and long-term 
success is less readily achievable, enabling differences in outcomes from ablation 
methods to be apparent.  
 
In contrast to previous studies, remote magnetic navigation was associated with 
significantly longer procedure and ablation time in our cohort. However, the remote 
magnetic navigation group had more cases with ≥3 inducible VT morphologies, 24% 
vs 7% p = 0.009. While not the procedural endpoint, the rate for elimination of all 
inducible VT was similar with magnetic navigation and manual groups, 49% vs. 41% 
p = 0.353, suggesting that the longer ablation and procedural times were related to the 
treatment of more VT circuits. The average fluoroscopy time was shorter with remote 
magnetic navigation, corrected for the length of the procedure was shorter, 4.2±3 
min/hr vs. 7.8±3.6 min/hr p<0.001, consistent with prior reports[18, 19]. Despite 
more extensive ablation in the remote magnetic navigation group, the overall rate of 
complications was similar to the manual ablation with no procedural mortalities and 
fewer major complications overall, which did not reach statistical significance.  
 
Few studies comparing remote magnetic navigation and manual VT ablation have 
suggested differences in long-term efficacy. Hendriks et al. compared remote 
magnetic navigation to contact force and non-contact force manual VT ablation to 
find higher acute success and improved long-term arrhythmia-free survival[10]. 
However, there were more idiopathic VTs treated in the remote magnetic navigation 
arm than the manual arms of the study (60/86 vs. 66/152, p<0.001), raising the 
possibility that the observed differences were driven by the type of VT treated. Dinov 
et al. showed in a cohort of 102 ischaemic cardiomyopathy patients that remote 
magnetic navigation had equivalent acute success compared to manual ablation with a 
non-significant trend towards improved long term survival from VT recurrence [20].  
The remote magnetic navigation group had shorter ablation times than the manual 
group in their cohort (1590 ± 1047.4s vs 2338 ± 1248s, p=0.049). The opposite trend 
in ablation time was seen in our cohort with remote magnetic navigation (4030±2143s 
vs. 2924±1849s, p=0.1), suggesting either more arrthymogenic substrate was 
identified or more substrate modification performed at ablation. Remote magnetic 
navigation but not ablation time predicted acute success and long-term outcomes in 
multivariate analyses (Table 3 and 4), indicating that the differences in outcomes were 
not driven by the amount of ablation. 
 
Patients with more extensive ischemic arrhythmogenic substrate may benefit the most 
from remote magnetic navigation guided VT ablation. Di Biase et al. showed that 
remote magnetic navigation guided VT ablation in patients with ischemic scar of 
large area (>60cm2) was able to provide higher density substrate mapping, lower 
mapping time, and led to longer ablation times compared to manual ablation [21]. At 
follow up, there was significantly longer VT free survival in the remote magnetic 
navigation group. While mapping time was not recorded in our procedures, we 
observed that fewer cases in the remote magnetic navigation group required multiple 
approaches for the ablation catheter for remote magnetic navigation compared to 
manual ablation, 5/69 (7%) vs. 14/70 (20%) p = 0.029, and fewer needing retrograde 
aortic access, 7/69 (10%) vs. 18/70 (26%) p = 0.017, suggesting that it may have been 
easier to achieve more complete endocardial mapping with the ablation catheter using 
remote magnetic navigation. In combination with greater stability of catheter tip 
position[12], this may enable more complete identification and modification of 
arrhythmogenic substrates. Interestingly, better long-term outcomes with remote 
magnetic navigation was not seen in the non-ischaemic cardiomyopathy subgroup. 
Improvements in endocardial substrate mapping and ablation would be expected to 
convey a smaller advantage in this patient group where mid-myocardial and epicardial 
substrates predominate and biophysical limitations of radiofrequency lesion formation 
poses a significant challenge for procedural efficacy. 
 
LIMITATIONS 
This study was not randomised and hence could be subject to confounding effects of 
selection and operator bias. However, the remote magnetic navigation group appeared 
to have more advanced arrhythmogenic substrate with more patients observed to have 
³3 inducible VT morphologies suggesting that selection bias may have acted against 
improved outcomes observed. The effect of operator was also investigated in 
multivariate analyses and found to be insignificant. Magnetic VT, a randomised 
multicentre clinical trial currently underway comparing remote magnetic navigation 
to manual ablation in patients with ischaemic cardiomyopathy and ICDs, will address 
the limitations of this and other previous studies to provide a more definitive 
comparison in the future. 
 
CONCLUSIONS 
Remote magnetic navigation appears safe and effective for VT ablation compared 
with manual ablation. In patients with ischaemic cardiomyopathy, remote magnetic 
navigation was associated with improved long-term clinical outcomes. The 
mechanism for this merits further study and may be due to advantages in remote 
magnetic navigation guidance for more complete endocardial mapping and ablation of 
arrhythmogenic substrates.   
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Table 1. Patient characteristics  
   
Manual  
 
n=58 
Remote 
magnetic 
navigation 
n=55 
p value 
 
 
Mean age +/- SD  54±22 57±16 0.766 
 
Male gender (%)  41 (71%) 31 (56%) 0.113 
 
VT type (%) 
 
Idiopathic (No structural heart 
disease) 18 (31%) 20 (36%) 0.076 
 Ischaemic cardiomyopathy 15 (26%) 22 (40%)  
 Non-ischaemic cardiomyopathy 25 (43%) 13 (24%)  
LV systolic function 
(%) Normal 12/37 (32%) 13/35 (37%) 0.895 
 Mild-moderately impaired 14/37 (38%) 13/35 (37%)  
 Severely impaired 11/37 (30%) 9/35 (26%)  
 
Recent LV function assessment not 
available 21 20  
RV systolic function  
(%) Normal 18/29 (62%) 16/30 (53%) 0.531 
 Mild-moderately impaired 11/29 (38%) 13/30  (43%)  
 Severely impaired 0/29 (0%) 1/30 (4%)  
 
Recent RV function assessment not 
available 29 25  
Biventricular 
impairment (%)  9/29 (31%) 13/30 (43%) 0.329 
ICD at the time of 
procedure (%)   32 (55%) 32 (58%) 0.514 
 
 
 
 
 
Table 2. VT ablation procedures 
 
 
Manual   
           n=70 
Remote magnetic 
navigation n=69 
p value 
 
Referral for VT ablation 
(%) Elective adission 43 (65%) 42 (62%) 0.684 
 
Emergency admission 23 (35%) 26 (38%) 
 First or redo procedure 
at WMH (%) First procedure  58 (83%) 55 (80%) 0.634 
 
Redo procedure  12 (17%) 14 (20%) 
 Approach used for 
catheter ablation  
 
LV endocardial via retrograde aortic 18 (26%) 7 (10%) 0.017* 
(%) LV endocardial via transseptal  26 (37%) 27 (39%) 0.809 
 
 
RV endocardial approach 34 (49%) 36 (52%) 0.735 
 
Epicardial  6 (9%) 4 (6%) 0.745 
 
Other 3 (4%) 0 (0%) 0.496 
 
More than one approached used  14 (20%) 5 (7%) 0.029* 
Procedure time in 
minutes mean±SD No structural heart disease 231±95 375±110 <0.001* 
 Ischaemic cardiomyopathy 345±87 425±117 0.018* 
 Non-ischaemic cardiomyopathy 295±94 495±112 <0.001* 
Ablation time in seconds  
mean±SD No structural heart disease 868±862 2661±1491 <0.001* 
 Ischaemic cardiomyopathy  2924±1849 4030±2143 0.1 
 Non-ischaemic cardiomyopathy 1759±1791 3985±2306 0.001* 
Average fluroscopy time 
±SD  (min) 
 
 
38.8±24.08 32.45±24.24 0.059 
Average fluroscopy time/average procedure time  
±SD (min/hr) 7.8±3.6 4.2±3 <0.001* 
Median number of VT 
morphologies 
(interquartile range) 
 
No structural heart disease 
Ischaemic cardiomyopathy 
Non-ischaemic cardiomyopathy 
 
1(1-1) 
1(1-2) 
1 (1-2) 
1(1-1) 
2 (1-3) 
2 (1-5) 0.105 
 
Number of cases with ≥3 
morphologies (%) 
 
5 (7%) 16 (24%) 0.009* 
 
Acute procedural 
outcome (%) Clinical VT non-inducible 42 (60%) 55 (80%) 0.011* 
 
Clinical VT more difficult to induce  10 (14%) 10 (15%) 1 
 
Clinical VT inducibility unchanged 8 (11%) 1 (1%) 0.033* 
 
Elimination of all inducible VT 29 (41%) 34 (49%) 0.353 
 
Procedural complication prevented 
assessment of success 4 (6%) 1 (1%) 0.681 
 
VT not inducible at baseline, success 
not assessable 6 (9%) 1 (1%) 0.116 
Procedural complications 
(%) Total 8 (11%) 9 (13%) 0.801 
 
Minor 2 (3%) 7 (10%) 
  Major 6 (9%) 2 (3%) 0.091 
 *Statistically significant on univariate analysis. 
 
 
Table 3. Predictors of acute procedural outcomes 
 
Acute procedural success (non-inducibility of clinical VT) 
Univariate predictors 
with p<0.20 
 
OR (95% CI) p value 
Multivariate 
predictors 
Adjusted OR 
(95% CI) 
Adjusted 
p value 
Remote magnetic 
navigation 
 
2.619 (1.229-5.583) 0.011 
Remote magnetic 
navigation 
2.750 (1.260-
6.002) 
0.011 
 
 
Emergency 
admission 
 
 
0.611 (0.288-1.229) 0.199    
Procedure ablation 
time (> median) 
 
 
0.196 (0.034-1.129) 0.121    
 
Procedural complications 
Univariate predictors 
with p<0.20 
 
OR (95% CI) p value 
Multivariate 
predictors 
Adjusted OR 
(95% CI) 
Adjusted 
p value 
Redo VT ablation 
 
Age >67 (3rd tertile) 
3.943 (1.402-11.086) 
 
5.559 (1.318-9.606) 
0.006 
 
0.009 
Redo VT ablation 
 
5.451 (1.030-
17.859) 
0.026 
 
RV impairment 
 
 
4.556 (1.130-18.364) 0.023 
 
Age >67 (3rd tertile) 
 
 
4.524 (1.220-
24.359) 
0.048 
 
LV impairment 
 
Biventricular 
impairment 
3.078 (0.817-11.601) 
 
4.000 (1.090-14.683) 
0.085 
 
0.051 
 
RV impairment 
 
 
4.289 (1.016-
20.144) 
0.045 
 
 
RV endocardial 
approach 
 
0.313 (0.106-0.923) 0.029 
    
Epicardial approach 
 
3.080 (0.722-13.133) 0.135  
  
Idiopathic VT 
 
0.384 (0.106-1.396) 0.134    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Univariate and Multivariate predictors of the primary endpoint in patients with 
ischaemic cardiomyopathy after single and multiple procedures 
 
Hazard of reaching the primary endpoint after a single procedure 
Univariate predictors 
with p<0.20 
 
 
HR (95% CI) p value 
Multivariate predictors 
with p<0.05 
Adjusted HR 
(95% CI) 
Adjusted 
p value 
Remote magnetic 
navigation 
 
0.466 (0.179-1.212) 
 
0.104 
 
Remote magnetic 
navigation 
0.240 (0.070-
0.821) 
0.023 
 
Emergency admission 
 
1.842 (0.702-4.832) 0.198    
Female gender 
 
1.968 (0.689-5.624) 0.189 
Emergency admission 
 
3.782 (1.080-
13.252) 
0.038 
 
Epicardial approach 
 
5.619 (0.655-48.166) 0.070    
 
Retrograde aortic 
approach 
 
 
2.034 (0.798-5.183) 0.122    
Multiple approaches 
 
 
4.765(1.425-15.935) 0.005 
    
 
 
Hazard of reaching the primary endpoint after multiple procedures 
Univariate predictors 
with p<0.20 
 
 
HR (95% CI) p value 
Multivariate predictors 
with p<0.05 
Adjusted HR 
(95% CI) 
Adjusted 
p value 
Remote magnetic 
navigation 
 
0.170 (0.046-0.632) 
0.002 
Remote magnetic 
navigation 
 
0.460 (0.227-
0.934) 
0.032 
 
Female gender 
 
2.505 (0.750-8.371) 
 
0.111    
 
Last procedure ablation 
time > median 
 
 
0.275 (0.056-1.344) 0.083    
 
Retrograde aortic 
approach 
 
 
3.374 (1.121-
10.156) 0.018    
Multiple approaches 
 
2.918 (0.865-9.850) 0.065    
 
 
 
 
 
 
 
 
 
 
Figure 1. Single procedure freedom from VT leading to implanted defibrillator 
shock, re-hospitalization, or repeat catheter ablation and death of any cause 
 
  
 
  
*adjusted p value, unadjusted p = 0.104 (Table 4) 
 
 
 
Figure 2. Multi-procedure procedure freedom from VT leading to implanted 
defibrillator shock, re-hospitalization, or repeat catheter ablation and death of 
any cause 
 
 
 
 
 
 
 
 
Figure 3. Multi-procedure freedom from recurrent VT in patients with structural 
heart disease and  ICDs 
  
    
  
 
 
 
 
 
 
 
Figure 4. Single procedure freedom from death of any cause in patients with 
structural heart disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
